After years of rising obesity rates in the US, the numbers dipped slightly during 2023, though experts disagree about the ...

Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug ...

Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...

Obesity is still a challenge for U.S. health. You might think that higher prices of food after the pandemic led to a decline ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

CINCINNATI — Since the summer of 2024, Dawnetra Blackwell has been on a mission to get kids moving and active in the way she ...

The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Nov. 26, 2024 — Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with ...

I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...